Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines

13 Apr 2022

Abstract excerpt

The aberrant activation of the phosphoinositide 3-kinase (PI3K)/ protein kinase B (AKT) pathway is common in pancreatic ductal adenocarcinomas (PDAC). The application of inhibitors against PI3K and AKT has been considered as a therapeutic option. We investigated PDAC cell lines exposed to increasing concentrations of MK-2206 (an AKT1/2/3 inhibitor) and Buparlisib (a pan-PI3K inhibitor). Cell proliferation,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Pancreatic and Hepatic Oncology Research
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35457111
DOI: 10.3390/ijms23084295

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell LinesPMID 35457111Read ↗

Molecular dissection of pancreatic cancer signaling: Toward targeted therapies for KRAS, MDM2-TP53, EGFR, and PI3K/AKT/mTOR.Semantic proximity Read ↗

Repurposing DPP-4 inhibitors as anticancer agents in KRAS-mutated pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

KRAS Pathway-based Therapeutic Approaches in Pancreatic Cancer.Semantic proximity Read ↗

Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.Semantic proximity Read ↗

Phosphoproteomics identifies PI3K inhibitor-selective adaptive responses in pancreatic cancer cell therapy and resistanceSemantic proximity Read ↗

Inhibiting CDK4/6 in pancreatic ductal adenocarcinoma via microRNA-21Semantic proximity Read ↗

Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic CancerSemantic proximity Read ↗

The Landscape of Pancreatic Cancer Therapeutic Resistance MechanismsSemantic proximity Read ↗

Transcriptomic and functional analysis of <i>ANGPTL4</i> overexpression in pancreatic cancer nominates targets that reverse chemoresistanceSemantic proximity Read ↗

Pathway-selective strategies reveal specific PI3K–mTOR inhibitors as key partners in KRAS G12D-targeted therapySemantic proximity Read ↗

Overcoming drug resistance in pancreatic cancer.Semantic proximity Read ↗

The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.